Sientra Inc (NASDAQ:SIEN) was the recipient of some unusual options trading activity on Monday. Investors purchased 2,186 call options on the stock. This is an increase of 2,566% compared to the average daily volume of 82 call options.

Large investors have recently modified their holdings of the company. Alliancebernstein L.P. grew its position in shares of Sientra by 18.8% during the 3rd quarter. Alliancebernstein L.P. now owns 21,500 shares of the medical instruments supplier’s stock worth $513,000 after buying an additional 3,400 shares during the period. Federated Investors Inc. PA grew its position in shares of Sientra by 19,162.9% during the 3rd quarter. Federated Investors Inc. PA now owns 66,457 shares of the medical instruments supplier’s stock worth $1,587,000 after buying an additional 66,112 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Sientra during the 3rd quarter worth approximately $3,767,000. AQR Capital Management LLC grew its position in shares of Sientra by 41.5% during the 3rd quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock worth $462,000 after buying an additional 5,675 shares during the period. Finally, Citigroup Inc. grew its position in shares of Sientra by 101.7% during the 4th quarter. Citigroup Inc. now owns 19,000 shares of the medical instruments supplier’s stock worth $241,000 after buying an additional 9,579 shares during the period. Institutional investors own 90.81% of the company’s stock.

Shares of NASDAQ:SIEN opened at $8.20 on Tuesday. Sientra has a one year low of $7.10 and a one year high of $26.79. The company has a quick ratio of 1.75, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The company has a market cap of $220.24 million, a PE ratio of -2.52 and a beta of -0.08.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.19). Sientra had a negative return on equity of 123.51% and a negative net margin of 121.28%. The business had revenue of $19.02 million for the quarter, compared to analyst estimates of $18.87 million. As a group, equities research analysts forecast that Sientra will post -2.84 earnings per share for the current fiscal year.

A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a research note on Friday, April 5th. Maxim Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Sientra in a research note on Monday, February 11th. ValuEngine downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Craig Hallum set a $23.00 target price on shares of Sientra and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Finally, William Blair downgraded shares of Sientra from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $20.44.

ILLEGAL ACTIVITY WARNING: “Sientra Sees Unusually Large Options Volume (SIEN)” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/sientra-sees-unusually-large-options-volume-sien-2/2982229.html.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Read More: Why do companies pay special dividends?

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.